/
Ingevity Corporation provides products and technologies that purify, protect, and enhance the world around us. Through a diverse team of talented and experienced people, we develop, manufacture, and bring to market solutions that are largely renewably sourced and help customers solve complex problems while making the world more sustainable.
$76.53
+$1.36 (+1.81%)
EOD Jul 17, 2026
Margins and capital returns are both well above average: 35.86% operating margin, ROIC at 26.30%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue declined 2.7% YoY. The question is whether this is cyclical or a structural shift.
Net debt of $1.26B represents 4.6x FCF, leverage limits flexibility.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1.18B
▼ -2.7% YoY
Net Income (TTM)
-$128M
▲ +61.2% YoY
Op. Margin
36.06%
▲ +0.4pp YoY
ROIC
29.98%
▲ +9.6pp YoY
Cash Flow & Balance Sheet
FCF (FY)
$274M
▲ +436.3% YoY
Op. Cash Flow (TTM)
$304M
▲ +157.5% YoY
Net Debt
$1.15B
Cash & Equiv.
$95M
5Y CAGR: -0.8%
5Y CAGR: +0.2%
Continue Research
Ingevity (NGVT) trades below a two-stage DCF intrinsic value of about $176.19 per share, so at $76.53 the stock looks undervalued (130.2% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Ingevity scores 64/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $176.19 per share for NGVT, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $132.14. At today's $76.53, that puts the stock about 130.2% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Ingevity scores 64 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 36.1% operating margin and a 30.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. NGVT currently trades below its estimated intrinsic value and scores 64/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.